STAT3-IN-13 NEW
| Price | $196 | $328 | $428 |
| Package | 2mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: STAT3-IN-13 | CAS No.: 2248552-86-3 |
| Purity: 98.89% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | STAT3-IN-13 |
| Description | STAT3-IN-13 is a potent STAT3 inhibitor.STAT3-IN-13 has antiproliferative and anticancer activity and acts by binding to the structural domain of STAT3 SH2.STAT3-IN-13 inhibits the phosphorylation of STAT3 Y705, which induces apoptosis and inhibits tumor cell growth and metastasis.STAT3-IN-13 can be used to study breast cancer and liver cancer. The study of breast cancer and hepatocellular carcinoma. |
| In vitro | STAT3-IN-13 (compound 6f), over a period of 48 hours, demonstrates anti-proliferative activity with IC50 values of 0.25, 0.11, and 0.55 μM for 143B, HOS, and MG63 cells, respectively [1].In the concentration range of 0.001-100 μM, STAT3-IN-13 (compound 6f) binds to STAT3 and interacts with STAT3^586-685 in a concentration-dependent manner, with a KD of 0.96 μM [1].Over a period of 24 hours at concentrations ranging from 0 to 1.0 μM in 143B and HOS cells, STAT3-IN-13 (compound 6f) inhibits STAT3 Y705 phosphorylation and suppresses STAT3 in tumor cells [1].At concentrations ranging from 0 to 1.0 μM over 48 hours in 143B cells, STAT3-IN-13 (compound 6f) induces apoptosis in a dose-dependent manner [1]. |
| In vivo | In vivo, STAT3-IN-13 (compound 6f), administered intraperitoneally at doses of 10-20 mg/kg twice daily for 4 weeks in nude mice, effectively blocks osteosarcoma growth and metastasis [1]. |
| Storage | Shipping with blue ice. |
| Solubility Information | DMSO : 80 mg/mL (183.28 mM), Sonication is recommended. |
| Inhibitors Related | Nifuroxazide | Balsalazide sodium hydrate | Scutellarin | 2-(1,8-naphthyridin-2-yl)phenol | CASIN | Diosgenin | Niclosamide olamine | Artesunate | Alantolactone | Stattic |
| Related Compound Libraries | Bioactive Compound Library | Inhibitor Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/5mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $1230.00/25mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $0.00/1kg |
VIP1Y
|
Hangzhou Lin'an tianhong biotechnology co.,ltd.
|
2024-07-26 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY